Total Funding
89
45
Total FundingPost-IPO Equity raised
Growth Score
1 pts
Heat Score
-18 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
102077
ProQR Therapeutics is a biotech company focused on developments of drugs to treat genetic disorders.
Aniz Girach: Chief Medical OfficerPast Role: Nightstar Therapeutics, CMO- Hilde van Hattum: Sr. Scientist Product Characterization and Bioanalytics
About the Company
ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipeline
includes QRX-704, QRX-504, QRX-421, QRX-323 etc.
